Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil

被引：6
|
作者：
Tam, Constantine [1 ,2 ]
Kuss, Bryone [5 ,6 ]
Opat, Stephen [3 ,4 ]
Boulos, Joy [7 ]
Marlton, Paula [8 ,9 ]
机构：
[1] St Vincents Hosp, Dept Haematol, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Dept Haematol, Melbourne, Vic, Australia
[3] Monash Med Ctr, Dept Haematol, Melbourne, Vic, Australia
[4] Monash Univ, Melbourne, Vic, Australia
[5] Flinders Univ S Australia, Dept Haematol, Adelaide, SA, Australia
[6] Flinders Med Ctr, Adelaide, SA, Australia
[7] Roche Prod Ltd, Sydney, NSW, Australia
[8] Princess Alexandra Hosp, Dept Haematol, Brisbane, Qld, Australia
[9] Univ Queensland, Sch Med, Brisbane, Qld, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2017年 / 47卷
关键词：
anti-CD20; monoclonal antibody; rituximab; obinutuzumab; CLL; ILLNESS RATING-SCALE; NON-HODGKIN-LYMPHOMA; RITUXIMAB; TRIAL; CLL; CYCLOPHOSPHAMIDE; FLUDARABINE; SURVIVAL; REGIMEN;
D O I：
10.1111/imj.13493
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with chronic lymphocytic leukaemia (CLL) are generally older, with many considered unfit' for fludarabine-cyclophosphamide-rituximab therapy. In these patients, the combination of obinutuzumab-chlorambucil may be an appropriate therapeutic choice. Obinutuzumab-chlorambucil has been demonstrated to improve overall survival rates compared to chlorambucil alone and to improve progression-free survival and overall response rates compared to rituximab-chlorambucil. This combination can lead to certain toxicities that need to be addressed through appropriate patient selection, pre-medication and management. In this paper, we discuss evidence-based and author-recommended practical management of first-line CLL patients receiving obinutuzumab-chlorambucil.
引用
收藏
页码：5 / 10
页数：6
相关论文
共 50 条
  • [41] Clonal Evolution In Patients With Previously Untreated Chronic Lymphocytic Leukemia
    Parikh, Sameer A.
    Rabe, Kari G.
    Smoley, Stephanie A.
    Wiktor, Anne E.
    Hanson, Curtis A.
    Shanafelt, Tait D.
    Van Dyke, Daniel L.
    BLOOD, 2013, 122 (21)
  • [42] A phase II study investigating safety and efficacy of dose reduced fludarabine, cyclophosphamide and obinutuzumab versus chlorambucil and obinutuzumab in untreated, comorbid, elderly patients with chronic lymphocytic leukemia (CLL)
    Mulligan, Stephen
    Tam, Constantine
    Badoux, Xavier
    Kuss, Bryone
    LEUKEMIA & LYMPHOMA, 2015, 56 : 25 - 26
  • [43] Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
    Soumerai, Jacob D.
    Mato, Anthony R.
    Dogan, Ahmet
    Seshan, Venkatraman E.
    Joffe, Erel
    Flaherty, Kelsey
    Carter, Jason
    Hochberg, Ephraim
    Barnes, Jeffrey A.
    Hamilton, Audrey M.
    Abramson, Jeremy S.
    Batlevi, Connie L.
    Matasar, Matthew J.
    Noy, Ariela
    Owens, Colette N.
    Palomba, M. Lia
    Kumar, Anita
    Takvorian, Tak
    Ni, Ai
    Choma, Morgan
    Friedman, Chaya
    Chadha, Puja
    Simkins, Elizabeth
    Ruiters, Jade
    Sechio, Sidney
    Portman, Daneal
    Ramos, Lauren
    Nolet, Natascha
    Mahajan, Neena
    Martignetti, Rosalba
    Mi, Joanna
    Scorsune, Krista
    Lynch, Julia
    McGree, Brianne
    Hughes, Stephanie
    Grieve, Clare
    Roeker, Lindsey E.
    Thompson, Meghan
    Johnson, P. Connor
    Roshal, Mikhail
    Huang, Jane
    Biondo, Juliana
    Wu, Qun
    Jacob, Allison
    Abdel-Wahab, Omar
    Zelenetz, Andrew D.
    LANCET HAEMATOLOGY, 2021, 8 (12): : E879 - E890
  • [44] Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN Study
    Leblond, Veronique
    Cantin, Guy
    Cortelezzi, Agostino
    Knauf, Wolfgang
    Tiab, Mourad
    Turgut, Mehmet
    Zaritskey, Andrey
    Merot, Jean-Louis
    Trunzer, Kerstin
    Robson, Susan
    Gresko, Ekaterina
    Stilgenbauer, Stephan
    Foa, Robin
    Bosch, Francesc
    BLOOD, 2017, 130
  • [45] POTENTIAL LONG-TERM COST SAVINGS DUE TO SIGNIFICANT CLINICAL BENEFIT OF OBINUTUZUMAB (GA101) IN COMBINATION WITH CHLORAMBUCIL IN PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
    Walzer, S.
    Tournier, C.
    Marino, J. P.
    Mueller, E.
    Duong, M.
    VALUE IN HEALTH, 2013, 16 (07) : A400 - A401
  • [46] Obinutuzumab in patients with previously untreated primary membranous nephropathy
    Du, Xuanyi
    Lin, Xiaojing
    Fu, Rao
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [47] Obinutuzumab in patients with previously untreated primary membranous nephropathy
    Du, Xuanyi
    Lin, Xiaojing
    Fu, Rao
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I720 - I721
  • [48] COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB/CHLORAMBUCIL VS RITUXIMAB/CHLORAMBUCIL IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
    Yagudina, R.
    Kulikov, A.
    Babiy, V. V.
    VALUE IN HEALTH, 2015, 18 (07) : A460 - A460
  • [49] RESULTS OF A PHASE II MULTICENTER STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE IN PTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
    Danilov, A.
    Yimer, H.
    Boxer, M.
    Di Bella, N.
    Babu, S.
    Li, J.
    Mun, Y.
    Skettino, S.
    Sharman, J.
    HAEMATOLOGICA, 2017, 102 : 71 - 71
  • [50] Serum sickness reaction to obinutuzumab in a patient with chronic lymphocytic leukaemia
    Elmanaseer, Oday
    Avelino, Alzira R. M.
    Azem, Amin
    Raval, Mihir
    BMJ CASE REPORTS, 2021, 14 (12)
12345